M. Fournier (Clichy, France), R. A. Stockley (Birmingham, United Kingdom)
The influence of long-lasting b-2 agonists on the flow of COPD
M. Yakimova (Tashkent, Uzbekistan)
|  |
Cardiovascular safety of salmeterol in patients with COPD
C. Reisner, C. Funck-Brentano, T. Fischer, P. Darken, K. Rickard (Research Triangle Park, United States Of America; Paris, France)
| |
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD
K. Knobil, C. Kalberg, A. Emmett, D. Horstman, K. Rickard, P. Wire (Research Triangle Park, United States Of America)
| |
Sustained FEV1 increases in COPD patients induced by salmeterol 50 mcg twice daily via the diskus inhaler
P. Wire, M. Watkins, C. N. Chang, C. Kalberg, K. Knobil, D. Horstman (Research Triangle Park, United States Of America)
| |
Salmeterol provides sustained health status improvement over 12 months in patients with COPD
R. Stockley, E. A. Davis, S. Sondhi, L. Rice, on Behalf of an International Study Group (Birmingham, United Kingdom; Research Triangle Park, United States Of America)
| |
Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD)
R. A. Stockley, N. Chopra, on Behalf of an International Study Group (Birmingham, United Kingdom)
| |
Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD)
R. A. Pauwels, P. M. A. Calverley, J. Vestbo, P. Jones, N. B. Pride, A. Gulsvik, J. Anderson, C. Maden, V. Percin, on Behalf of the TRISTAN Study Group (Gent, Belgium; Liverpool, London, Middlesex, United Kingdom; Hvidovre, Denmark; Bergen, Norway)
| |
Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease
J. Vestbo, P. M. A. Calverley, R. Pauwels, P. Jones, N. B. Pride, A. Gulsvik, J. Anderson, J. B. Soriano, C. Maden, on Behalf of the TRISTAN Study Group (Hvidovre, Denmark; Liverpool, London, Greenford, United Kingdom; Gent, Belgium; Bergen, Norway)
| |
COPD and Seretide: a multi-centre intervention and characterisation (COSMIC) study: rationale and baseline characteristics
E. F. M. Wouters, on Behalf of the COSMIC Study Group (Maastricht, The Netherlands)
| |
Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year
P. M. A. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. B. Pride, A. Gulsvik, J. Anderson, C. Maden, on Behalf of the TRISTAN Study Group (Liverpool, London, Uxbridge, United Kingdom; Gent, Belgium; Hvidovre, Denmark; Bergen, Norway)
| |
Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study
P. Lange, C. Saenz (Copenhagen, Denmark; Buenos Aires, Argentina)
| |
Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study
F. Egede, G. Menga (Svendborg, Denmark; Buenos Aires, Argentina)
| |
Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD
R. Dahl, A. Cukier, H. Olsson (Aarhus, Denmark; Sao Paulo, Brazil; Lund, Sweden)
| |
Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD
J. Milanowski, S. Nahabedian (Lublin, Poland; Buenos Aires, Argentina)
| |
Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD
J. Korsgaard, R. Sansores (Silkeborg, Denmark; Mexico City, Mexico)
| |
Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility
M. Bogdan, A. Eliraz, C. Mckinnon, U. Nihlen, E. Radeczky, S. Soliman, D. Osmanliev (Bucharest, Romania; Rehovot, Israel; Glasgow, United Kingdom; Lund, Sweden; Százhalombatta, Hungary; Sofia, Bulgaria)
| |
Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler
G. Johansson, C. J. Álvarez, P. D. M. Coenen, A. Eliraz, C. Mackinnon, S. Soliman, T. Tornling, E. Ståhl, E. Radeczky (Lund, Sweden; Madrid, Spain; , ; Rehovot, Israel; Glasgow, United Kingdom; Százhalombatta, Hungary)
| |
Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD)
A. Eliraz, T. Bengtsson, M. Bogdan, G. Johansson, D. Osmanilev, S. Soliman, G. Tornling, (Rehovot, Israel; Lund, Uppsala, Sweden; Bukharest, Romania; Sofia, Bulgaria)
| |
Inhaled corticosteroid therapy on admission of hospitalized patients with COPD
D. Arsenault, J. Godin, D. M. Bowie, R. A. McIvor (Halifax, Canada)
| |
Comparison of the effectiveness of parenteral and nebuliser steroid in COPD exacerbations
A. Mirici, M. Meral, M. Akgun, U. Tutar, S. Kiris (Erzurum, Turkey)
| |